US Bancorp’s VYNE Therapeutics VYNE Stock Holding History

US Bancorp’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-4,444	Closed	-$10.4K	–	4109
2023 Q4	$10.4K	Hold	4,444	–	–	﹤0.01%	3307
2023 Q3	$18K	Buy	+4,444	New	+$19.4K	﹤0.01%	2936

Other funds holding VYNE

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

AlphaCentric Advisors San Juan, Puerto Rico $100M AUM

EAM

Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

US Bancorp's VYNE Position: Q1 2024 in Review

US Bancorp sold out of VYNE Therapeutics (VYNE) in Q1 2024, closing a stake of 4,444 shares — an estimated $10.4K sold.

US Bancorp first reported a position in VYNE in Q3 2023 and held it in 2 quarters. The position peaked at $18K in Q3 2023. 32 funds tracked by Wall St. Rank hold VYNE as of Q1 2024.

US Bancorp reported no remaining VYNE Therapeutics position as of Q1 2024 after selling out during the quarter.
US Bancorp sold 4,444 VYNE Therapeutics shares in Q1 2024, an estimated $10.4K.
US Bancorp first reported a position in VYNE Therapeutics in Q3 2023 and held it in 2 quarters.
US Bancorp's VYNE Therapeutics position peaked at $18K in Q3 2023.
32 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2024.

Based on US Bancorp's 13F filing for Q1 2024, filed 8 May 2024.